Freakish Midwest tornados, devastating wildfires, extreme droughts, abnormal floods – all signal the onset of a changing global climate. There’s overwhelming concern about climate change, but it’s difficult to achieve consensus on actions to mitigate it. The COP 26 UN Climate Change Conference last November was a step in the right direction, spurring global commitments and serving a clear notice that the era of coal is rapidly coming to an end. Three dozen countries, including the United States, pledged to stop funding fossil fuel projects abroad by the end of this year, and more than 40 countries promised to phase out coal-fired power, the planet’s most carbon-intensive energy source. Largely due to capitalism, the shift to renewables is building a real head of steam. However, renewables alone cannot meet global energy needs. Solar and wind provide clean renewable energy when the sun is shining or the wind is blowing, but, if it’s cloudy and calm, they don’t produce much of anything. Since the technology hasn’t been developed to easily and cheaply store electricity in large quantities, other energy sources must fill this intermittency gap. Without 24/7 base-load producers, there currently isn’t enough consistent uninterrupted energy to sufficiently supply the grid, no matter how many solar or wind facilities get tacked on. Excluding fossil fuels, there’s currently only one real viable option for reliable 24/7 base-load electricity – nuclear power. Clean, safe and affordable, nuclear power is the only known low-carbon reliable power source that can meet both current and future base-load electricity demands while reducing air pollution and mitigating climate change. U.S. nuclear power plants already generate nearly 20% of the U.S.’s electricity and 55% of its carbon‐free electricity. Nuclear power requires use of U3O8, the most stable form of uranium oxide. It is commonly found in nature, but extraction is only economically viable from rich deposits. The largest producer of uranium in the U.S. is Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR). The leading U.S. diversified uranium miner, Energy Fuels is also the country’s leading conventional producer of vanadium and, importantly, began production of rare earths in 2021 at a stage more advanced than any other U.S. company. These are all designated as critical minerals by the U.S. government for national security as well as economic growth and stability. Energy Fuels’ uranium production portfolio stands apart in the world. The company has more uranium production facilities, more production capacity, and more in-ground resources than any other company in the United States. In fact, the company’s assets have produced over one-third of all U.S. uranium over the past 15 years and are uniquely positioned to increase production to meet new demand – and demand is expected to surge along with uptake. There are substantial direct drivers to increased uranium demand. Nuclear already provides a large portion of the nation’s electricity, and any real increase in electricity demand would require significant new nuclear capacity. It’s also the only known clean, safe, reliable base-load provider of carbon-free electricity in the transition to renewables. In addition and of substantial note, China is planning at least 150 new nuclear reactors in the next 15 years and has started building its first small modular reactor (“SMR”). Small modular reactors represent a new approach and could change the landscape of nuclear power. This “new generation of nuclear reactors could hold the key to a green future”, as heralded and headlined in a recent Time magazine article. Current nuclear power plants run most efficiently at full blast, which makes it difficult to adapt to a grid increasingly powered by variable sources (again, not every day is sunny or windy). This next generation of nuclear technology will be more flexible, able to adapt and respond quickly to the ups, downs and intermittency in supply and demand. The new generation of reactors differentiate from old-school reactors in size, scale, approach, safety, and application. With few operators in the space, the technology and opportunity have attracted notable interest and financial backing from Silicon Valley, Bill Gates, and the U.S. Department of Energy. Smaller reactors could be built in factories, ensuring quality control, and deployed to remote locations that lack wind, sun or other resources for energy production. They also can be purpose built to need, customized for use, and easily scaled. This exciting new technology to achieve carbon-free energy has potential to supplement other energy sources or even become a dominant method of energy production. Uranium demand should increase in lock step as the technology scales. In its annual long-term analysis on the future of the energy economy, BloombergNEF outlines three climate scenarios that achieve net-zero emissions by 2050. Each of Bloomberg’s scenarios describe major transformations in the primary energy supply, and nuclear remains a critical portion of all three scenarios. In the scenario that reduces fossil fuel use the most, nuclear makes up a whopping 66% of primary energy in 2050, compared with 5% today. This all adds up to a nuclear power renaissance, and demand for uranium is likely to remain unabated as the entire world continues to decarbonize. Much maligned uranium could be what ultimately saves the planet. For more information, visit the company’s website at www.EnergyFuels.com. NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU

• The Harris Poll conducted a survey on behalf of Delic Holdings, polling 2,037 adults ages 18 and older, 953 of whom suffer from anxiety/depression/PTSD
• The survey revealed that 65% of Americans living with anxiety/depression/PTSD believe that psychedelic medicine should be available to patients with treatment-resistant conditions
• 66%, 62%, and 56% are open to pursuing ketamine, psilocybin, and MDMA, respectively, to treat anxiety/depression/PTSD if these psychedelic drugs were each proven more effective than prescription medication with fewer side effects

Though the U.S. government has not yet federally recognized a medical use for most psychedelic drugs, research by renowned universities and companies like Delic Holdings (CSE: DELC) (OTCQB: DELCF) has been ongoing, partly charging what has come to be referred to as the psychedelic renaissance. Research has so far shown that the drugs – ketamine, psilocybin, MDMA (also known as ecstasy), and LSD – could potentially remedy mental conditions such as post-traumatic stress disorder (“PTSD”), depression, and addiction. There is also growing evidence that psychedelic drugs’ action in the brain differs from addictive drugs’ (https://ibn.fm/ioaZy). “One of the key mooted advantages of psychedelics over existing drugs is that they work holistically to make the neuroplastic brain more malleable, therefore freeing people from long-held beliefs and memories – opening them evermore to new concepts and states of mind. Thus, they allow the brain to reset and rewire itself, rather than simply dampening down symptoms and even causing serious side-effects,” reads an article published in The Guardian (https://ibn.fm/7ihOZ). In describing this family of promising medicines, Delic Co-founder and CEO Matt Stang similarly highlighted their “potential to be more effective than traditional drugs with minimal side effects, giving people their best lives back.” Stang’s comments are contained in a recent announcement in which Delic, a company making a mark in the psychedelic wellness scene, reported the findings of a survey it had commissioned (https://ibn.fm/rV24B). According to the survey conducted by The Harris Poll, 65% of Americans who suffer from anxiety/depression/PTSD believe that psychedelic medicine (ketamine, psilocybin, and MDMA) should be made available to patients with treatment-resistant anxiety, depression, or PTSD. Additionally, 63% of Americans who have used prescription medications to treat anxiety/depression/PTSD noted that while the medication helped, they still experienced residual feelings of anxiety, depression, or PTSD. Eighteen percent also said the prescribed drugs worsened their condition or did not improve it at all. Eighty-three percent of Americans living with anxiety, depression, or PTSD would be open to pursuing alternative treatments proven to be more effective than prescription medication with fewer side effects. More specifically, 66%, 62%, and 56% would be open to pursuing treatment using ketamine, psilocybin, and MDMA, respectively, if each was proven more effective than prescription drugs with fewer side effects. “We are witnessing a silent crisis impacting people across the globe exacerbated by an ongoing pandemic, and the results of this survey should compel more medical professionals and lawmakers to support in-depth studies on the therapeutic benefits of psychedelic medicine,” added Stang. The survey was conducted online within the United States in early December among 2,037 adults aged 18 or older, 953 of whom suffer from anxiety/depression/PTSD. It was not based on probability sampling. Founded in 2018, Delic is a leader in new medicines and treatments for a modern world and is committed to providing education, research, and treatment options to the masses in the field of psychedelics through an umbrella of related businesses that includes the largest chain of psychedelic wellness clinics with Ketamine Wellness Centers (“KWC”) and Ketamine Infusion Centers (“KIC”); media properties Reality Sandwich and Delic Radio; Delic Labs, the only licensed entity by Health Canada to exclusively focus on the R&D of psilocybin vaporization products; and Meet Delic, the largest psychedelic wellness event. For more information, visit the company’s website at www.DelicCorp.com and the Meet Delic conference website at www.MeetDelic.com. NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF

• CNS Pharmaceuticals received approval from swissethics for its potentially pivotal study of Berubicin, a novel anthracycline for the treatment of Glioblastoma Multiforme (“GBM”)
• The approval is the first from a European Ethics Committee
• The company, which dosed the first patients in its Berubicin program in September, has selected multiple clinical sites across the U.S., Spain, France, Italy, and Switzerland
• CNS recently closed an $11.5 million private placement
• It intends to use the net proceeds to fund its clinical trials and preclinical programs, other R&D programs, and for general corporate purposes

Clinical stage biotechnology company CNS Pharmaceuticals (NASDAQ: CNSP) is celebrating a significant milestone as it journeys toward its potentially pivotal study of Berubicin for the treatment of Glioblastoma Multiforme (“GBM”). The company announced December 2 that it had received approval from swissethics, the umbrella organization of the cantonal Ethics Committees in Switzerland (https://ibn.fm/NisfL). The first from a European Ethics Committee, the approval partly fulfills CNS’s goal of seeing Berubicin approved for the potential treatment of GBM globally. “This terrible disease does not discriminate on the basis of geography or anything else: Patients in Europe are as desperate as patients in the United States, and treating patients is not only why we do what we do, but how we do it as well. Driving patient enrollment is how we advance Berubicin’s development, and opening additional clinical sites around the globe is the pivotal piece that allows us to ramp up our efforts and move toward data,” stated CNC Pharmaceuticals CEO John Climaco. So far, the company has selected tens of clinical sites across the United States, Spain, France, Italy, and Switzerland. In addition, CNS has already dosed the first patients in its Berubicin clinical development program, with a September 30, 2021 announcement noting that additional patient enrollment, randomization, and dosing was well underway in the United States (https://ibn.fm/qI7q2). Berubicin mid last year received the U.S. Food and Drug Administration (“FDA”) Fast Track Designation as well as an Orphan Drug Designation (https://ibn.fm/PSSiU). Notably, the former designation helps facilitate the development and expedited review of drugs with the potential of treating serious conditions with high unmet medical needs, thereby underlining the seriousness of GBM, one of the most aggressive, deadly, and treatment-resistant cancers that form in the brain. While chemotherapy medications are usually prescribed to patients living with the condition, results are underwhelming, if not devastating. According to CNS, the current standard of care is ineffective in about 60% of patients. GBM is the most common malignant brain and central nervous system tumor accounting for 47.7% of all cases, according to data from the American Association of Neurological Surgeons (“AANS”). Its prevalence within a population of 100,000 people stands at 3.21. But despite this low incidence rate, the disease is lethal – only 40% of patients survive in the first year after diagnosis and 17% in the second year. Moreover, it can cause death in six months or less (https://ibn.fm/wU6vY). In this regard, the recent approval, as well as CNS’s dosing efforts, offer a robust foundation for a potentially pivotal global trial. The adaptive, multicenter, open-level, randomized, and controlled study will evaluate Berubicin in adult patients with recurrent GBM (WHO Grade IV) after failure of standard first-line therapy. About 243 patients with GBM after failure of standard first-line therapy will be randomized in a 2:1 ratio to receive Berubicin or lomustine, a chemotherapy drug, in order to evaluate overall survival, the primary endpoint of the study. It is noteworthy that Berubicin is the first anthracycline to cross the blood-brain barrier. It evidences effectiveness in treating GBM. “[Anthracycline] is a classic drug that’s been around for 60 years. It’s the first line therapeutic for all sorts of difficult-to-treat cancers. But no one has been able to get a drug like this across the blood-brain barrier until our Founder modified the classic anthracycline molecule to be more effective in crossing the blood-brain barrier,” said Climaco during an October interview with Proactive (https://ibn.fm/EJjMb). Meanwhile, CNS Pharmaceuticals recently closed a previously announced private placement, priced at-the-market under Nasdaq rules, of over 12,105,264 shares of common stock (or pre-funded warrants in lieu thereof), raising gross proceeds of $11.5 million (before deductions). CNS intends to use the net proceeds to fund its clinical trials and preclinical programs, other R&D operations, and for general corporate purposes (https://ibn.fm/aTRJE). For more information, visit the company’s website at www.CNSPharma.com. NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• FuelPositive has hit multiple milestones throughout 2021, starting with its rebranding in January that ushered it into the world of green hydrogen and ammonia
• In March, the company acquired the intellectual property for its green ammonia production technology
• In May, FuelPositive began building its prototype production systems in collaboration with the National Compressed Air in Toronto and is on track to launch multiple real-world demonstration pilot projects throughout 2022
• The modular, scalable green ammonia production systems offer numerous benefits, including zero carbon emissions and cheaper production costs than traditional grey ammonia production

On January 19, 2021, shareholders, during the annual general and special meeting, approved the rebranding of EEStor Corporation as FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF) (https://ibn.fm/IY2z2), ushering the company into the rapidly burgeoning global hydrogen economy and subsequently into the green ammonia (“NH3”) segment, expected to grow at a 54% CAGR between 2020 and 2025 (https://ibn.fm/Fj9kO). Since then, FuelPositive has maintained a laser focus, driven by the mission to become a leader in fighting climate change by creating and developing practical, clean, and sustainable carbon-free solutions that can be implemented economically and at present. Its flagship offering – a proprietary, modular, scalable system that uses sustainable energy to produce green ammonia by combining nitrogen from the air with hydrogen extracted from water using a sustainable source of electricity – is intended to solve numerous problems, including the difficulty in storing and transporting hydrogen as well as the carbon emissions associated with traditional (“grey”) ammonia production. FuelPositive added this green ammonia production technology, a brainchild of Dr. Ibrahim Dincer and his research team at Ontario Tech University, to its intellectual property (“IP”) portfolio in March 2021 following an IP purchase agreement. “In May, we formed our manufacturing partnership with National Compressed Air to build our prototype systems; in June, we filed for our provisional patent and began to build our prototype production systems. Since then, we have raised over CA$12 million, which will cover our costs to build a number of green NH3 production systems. We are on track to launch multiple real-world demonstration pilot projects to showcase our technology throughout 2022,” said FuelPositive CEO and Board Chair Ian Clifford in a November 18 corporate update in which the company released an operational costing model and the timeline for its green ammonia technology (https://ibn.fm/STwU1). As part of the update, and based on a case study conducted in Manitoba, Canada, FuelPositive noted the green anhydrous ammonia produced by its system is about 40% cheaper to an end-user than grey ammonia. Accordingly, it offers additional benefits such as independence from the wildly volatile supply chain associated with grey anhydrous ammonia; on-site production that can be scaled depending on the demand and requirements; and a stable, predictable, and highly competitive cost per metric ton of producing green ammonia compared with the delivery price of an equivalent quantity of grey anhydrous ammonia. The company’s green ammonia system is transportable and modular, built to shipping container configurations – 20- and 40-foot containers, consumes less energy than conventional ammonia production, and does not have a carbon footprint. And as Clifford reiterated during a recent interview with The Tactical Leader Podcast, the company’s commitment to sustainability and environmental preservation extends beyond just producing green ammonia:  “. . . we look seriously at the impact of every step of our technology, not just the outcome of the product being carbon-free or non-polluting,” said Clifford. “Where does the steel come from that builds our systems? Where are the different technologies sourced? Where are the different raw materials from? It’s a real ‘cradle to cradle’ attitude in terms of our impact.” (https://ibn.fm/akJj7). Clifford also touched on the various applications of green ammonia, including as a fertilizer in the agriculture sector, fossil fuel replacement for the transportation sector, and a hydrogen storage medium (energy storage). In addition, 2021 represented remarkable milestones regarding the company’s engagement with investors and shareholders. In July, FuelPositive common shares debuted on the OTCQB Venture Marketplace, presenting a unique opportunity to increase its investor audience, visibility, and liquidity (https://ibn.fm/ToQXC). Similarly, FuelPositive participated in the H.C. Wainwright 23rd Annual Global Investment Conference held September 13-15, 2021. For more information, visit the company’s website at www.FuelPositive.com. NOTE TO INVESTORS: The latest news and updates relating to NHHHF are available in the company’s newsroom at https://ibn.fm/NHHHF

• Nemaura Medical is a medical technology company focused on developing non-invasive wearable diagnostic devices
• The company recently announced the rollout of its Miboko application by targeting insurers and employers
• In 2019, over $760 billion was spent on diabetes-related health care, equating to $9,000 per diabetic patient compared to $1,600 for a non-diabetic individual
• The Miboko application provides users with an efficient and accurate means of tracking their day-to-day glycaemic levels, a key determinant of overall metabolic health

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announced that it would launch Miboko, the company’s new metabolic health program using a non-invasive glucose sensor, for the use of employers and insurers worldwide. Nemaura Medical aims to promote the broad penetration and adoption of the Miboko device as a form of preventative medicine for a broad user base. The company opts to pursue the above commercial distribution channels to ensure the device’s successful rollout and adoption (https://ibn.fm/Yd5xE). Over 420 million people globally are currently living with diabetes, with prediabetic cases totalling almost three times that number. Meanwhile, and in the US alone, over $760 billion was spent on diabetes-related health care expenditures during 2019, equating to an average annual spend upwards of $9,000 per diabetic patient compared to approximately $1,600 for a healthy individual (https://ibn.fm/TBsWX). The Miboko application, a service offering that has been in development over the past 18 months, uses a non-invasive glucose sensor to measure and monitor users’ blood sugar levels, which are based on glucose tolerance or insulin resistance. The device is then linked to an AI mobile application, which seeks to provide users with personalized information by tracking their metabolism. Users will be able to find out how well their body responds to sugar through their metabolic health score — and how what they eat and what they do every day uniquely affects their metabolic health. Nemaura Medical believes the Miboko application could address a significant mass-market opportunity, benefitting roughly a third to half of the global population. The human body’s ability to metabolize sugar has been a key influential factor in determining one’s appetite, weight, sleep quality, and energy and mood levels and even plays a critical factor in chronic diseases (beyond just diabetes) like heart disease and dementia. “Introducing Miboko to the population at-large through employers and insurers will allow Nemaura to reach a much wider audience in a much faster fashion than solely relying on a direct-to-consumer campaign, and in the Western world, these institutions are the most reliable gateway toward wider adoption of preventative health maintenance practices,” commented Nemaura CEO Dr. Faz Chowdhury. In addition to following their day-to-day metabolic health on the application, Miboko users will also receive weekly and monthly reports that show and explain their body’s unique metabolic health score whilst providing a breakdown of how each of their habits impacts their overall health and wellbeing. Historically, diabetic and near-diabetic patients have monitored their blood sugar levels by collecting blood capillary samples, which have subsequently been analyzed by an accredited laboratory (https://ibn.fm/zIK2Z). Through the launch of the Miboko application, Nemaura Medical has sought to democratize access to blood sugar testing, enabling millions of individuals around the world to quickly, accurately and painlessly track their glycaemic levels – a significant step towards ensuring their long-term health. For more information, visit the company websites at www.NemauraMedical.com. For more information on Miboko, visit www.Miboko.com. NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD

• Since Summer 2021, Friendable has been searching for the right music distribution platform to pair with its successful flagship offering, Fan Pass Live
• The acquisition of Artist Republik brings an additional 100,000 artists to the platform and an extensive tech deck that will benefit all parties
• The Artist Republik acquisition provides independent artists with access to a distribution offering, which they would not have unless they paid additional for management and were assigned to a record label

Mobile technology and marketing company Friendable (OTC: FDBL) is releasing more details about the recent acquisition of Artist Republik, a reputable music distribution company, and how it affects the Fan Pass Live artist streaming platform. Since this last summer, Friendable has been looking to acquire a distribution company, platform, or service. The goals for its target acquisition candidate were related to historical and ongoing revenues, technology, services, industry relationships, and an active artist database that is fitting to the service offering that is already being well received by artists on the Fan Pass Live platform (https://ibn.fm/YG86S). “Artist Republik has experienced great momentum in music distribution, and now Friendable and Fan Pass are the beneficiaries of approximately 100,000 artists alongside these revenues that exceeded $450,000 in approximately eight months of 2021, of which our combined audit and 10k will provide all the details when filed,” Friendable CEO and Co-Founder Robert A. Rositano, Jr. explained the reasons behind the acquisition. “We also have the need to update technologies, bug fix, and expand resources to increase these current and historical revenues, so it was a real no-brainer for us to pursue the opportunity and, ultimately, complete the acquisition of Artist Republik. It was a bonus to have such great synergies with our branding, marketing, people, technology, and relationships, as well.” The offering provided by Artist Republik is much like what a manager and label would offer to a recording artist, but without the excessive rates and fees. Fan Pass Live platform artists will now be able to access the same kind of representation (on a virtual level) that they would receive if they brought on their own manager or label, while maintaining their ability to remain independent in the industry. In addition to bringing 100,000 more artists to the Fan Pass Live platform, the acquisition of Artist Republik has tripled the company’s tech deck. Together, between the Fan Pass Live artist platform and Artist Republik’s distribution resources, Friendable has created “the real deal” for artists and an exciting community for fans. Rositano, Jr. explained that, with a focus on supporting all existing artists, marketing and upgrading technology for expansion deployment, the Fan Pass Live team has already made impressive strides in bulking up technology and addressing issues that are currently holding back certain revenue channels that are just bursting with opportunity and artist orders. “We see it; we have our teams managing every aspect; and once we have ensured they are solid for growth, we will flip all the switches to green once again,” he said. “I believe we will not only scale existing revenues, but cross-promoting the Fan Pass Live service offerings will allow us to scale revenues on both sides from this huge influx of approximately 100,000 new artists alone, prior to any additional marketing efforts, we also intend to roll out shortly.” The Fan Pass Live platform is available for download as an Apple or Google app and can be downloaded from each respective app store. Fan Pass offers users a seven-day free trial, which includes the VIP all-access pass. After the trial, fans pay $2.99 per month for the subscription to the platform. Artists receive up to 40% of this subscription as revenue sharing. For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

• StraightUp received its early exploration permit that allows it to begin exploration activities on the eastern block of its RLX North property
• The company will be taking a systematic approach to developing and testing gold targets as it plans to execute its 2022 work programs which will include drilling prospective targets in the summer
• This approval strengthens StraightUp’s commitment to the Red Lake Mining District, having expressed the intention to acquire 100% undivided interest in the RLX property back in September 2021
• StraightUp also announced the appointment of Jacqueline Collins as the company’s new Corporate Secretary

StraightUp Resources (CSE: ST) (OTCQB: STUPF) has, since its inception, remained committed to pushing the envelope with mineral exploration and the acquisition of mineral property assets in North and South America. Its flagship property, a 10,000-hectare tract of land located in the Red Lake District, has shown great promise in gold mining. Following extensive studies, surveys, and tests on the property, the company is expected to proceed within its 2022 work programs, including drilling the most prospective targets in the summer. In September 2021, StraightUp completed a high-resolution heli-borne magnetic survey (“MAG”) on their optioned RLX property (https://ibn.fm/FqVjl). Fast forward to 2022, and the company has received its early exploration permit (“PR-21-000261”) from the Ministry of Northern Development and Mine, Natural Resources and Forestry (“NDMNF”) (https://ibn.fm/yFUES). This permit allows StraightUp to proceed with mechanized drilling along with ground geophysical surveys that require a generator for a period of three years. The pass, however, only covers the eastern block of the RLX north property, a high-priority exploration target given that the majority of the historic and current production from the Red Lake district has been mined within proximity to this location. When speaking on the permit approval, Mark Brezer, the President of StraightUp, noted: “We are now in an excellent position to move forward and plan a drill program on both of these RLX properties for this year. The latest results, combined with our extensive data set from previous exploration, strengthen our commitment to the Red Lake Mining District and its potential for legendary, high-grade gold discoveries.” StraightUp will be relying on detailed data compilation that, so far, includes interpretation of the MAG survey conducted back in 2021, coupled with clear regional structural interpretation to pinpoint the highest priority targets for Orogenic gold occurrences. In addition, the company is taking on a systematic approach to developing and testing gold targets. It is confident that the investments so far will pay off throughout the 2022 calendar year, particularly in growing shareholder value. The RLX North and South properties are located 25km southeast of the town of Red Lake. The property has been known for its diamond drill holes dating back to the early 1980s and over $1 million spent on drilling, line cutting, intellectual property, soil geochemical surveys, and geophysical surveying. StraightUp also announced the appointment of Jacqueline Collins as the company’s new Corporate Secretary effective January 4, 2022. Ms. Collins will lend over 30 years of experience as a legal administrator, paralegal, and corporate secretary, having worked at independent and national law firms and with public resource companies. For more information, visit the company’s website at www.StraightUpResources.com. NOTE TO INVESTORS: The latest news and updates relating to STUPF are available in the company’s newsroom at https://ibn.fm/STUPF

• Flora Growth just announced the production of its first batch of crude oil through its newly constructed facility in Colombia
• The company has also initiated the EU-GMP certification process that will allow it to target international medical cannabis markets
• Flora Growth also announced the appointment of Tim Leslie as Chairman of its newly established Advisory Board
• Mr. Leslie will play a key role in advising the company on how best to navigate the regulatory framework of building a truly global company
• 360 Financial, Inc. announced the purchase of 13,162 Flora Growth shares as of Q4 2021

Flora Growth (NASDAQ: FLGC) set out to increase sales and grow its market share for the 2022 calendar year, intending to assert its position as a leader in the global CBD sector. Barely a month into the new year, it has already achieved some key milestones that only offer a glimpse into the scale at which this company plans to operate for the rest year. On January 11, Flora Growth announced the production of its first batch of crude oil through its newly constructed extraction facility in Colombia. This was achieved through Cosechemos, a wholly-owned subsidiary that also initiated the process to become EU-GMP certified (https://ibn.fm/crlZX). In December 2021, Cosechemos successfully extracted the first batch of High-THC crude oil. It later submitted it to the Colombian Government per the requirements for obtaining Flora’s 2022 quota for THC derivatives. This showed the facility’s capacity and potential to serve as a primary processing hub for Flora Growth. So far, it is equipped to facilitate both drying and processing of all the company’s cultivated flower into finished, packaged dry flower and extracted material that is then sold domestically, in Colombia, and exported to wholesale cannabis markets abroad. “Global cannabis markets are growing at an incredible rate, and Flora is ready to meet that demand for cannabis-derivatives with the completion of our new EU-GMP compliant extraction facility in Colombia,” noted Luis Merchan, the President and Chief Executive Officer (“CEO”) of Flora Growth. With the completion of the EU-GMP certification, coupled with Flora’s recent Good Agricultural and Collection Practices (“GACP”) certification, the company will be poised to target the international medical cannabis markets. The goal is to disrupt this industry globally, leveraging its cost advantage given that its outdoor-cultivated cannabis is grown at as little as 6 cents per gram. “This is another major step for Flora Growth, as we are now in a position to seek EU-GMP certification, with the ultimate goal of disrupting the global cannabis derivatives market with our low-cost product,” noted Mr. Merchan. “Further, the completion of the facility immediately allows us to supply extracts and derivatives to our CPG portfolio, including Flora Beauty and Kasa brands, unlocking additional cost efficiencies,” he added. Jason Warnock, the Chief Research Officer (“CRO”) of Flora Growth, is confident that this new Colombia facility will have long-term benefits given the potential that the cannabis derivatives market currently has. He is also optimistic that it will help increase the range of the company’s products for a growing international medical market. Flora Growth also recently established an Advisory Board in a move that seeks to develop the company’s corporate structure and include a robust roster of human capital. Its most recent addition to this Board is Tim Leslie, an accomplished business leader, and cannabis industry expert, who will now serve as its Chairman (https://ibn.fm/xovdb). Mr. Leslie will lend over two decades of experience working at Amazon and his law educational background from Yale. He has made a name for himself working with scaling companies, building and managing Amazon’s international legal team, and even overseeing the global launch of Amazon Prime Video. Mr. Leslie has also served as the CEO of Leafly, one of the world’s most authoritative digital cannabis data sources. He has also been on the board of various renowned cannabis companies. “We are pleased and honored to have Tim join us as the first Chairman of our Advisory Board,” noted Mr. Merchan. “We will look to our newly established Advisory Board for counsel on how to amplify our growth opportunities both domestically and internationally. Tim will play a key role in advising on how best to navigate the regulatory framework of building a truly global company, something he specifically worked on in his time at Amazon,” he added. Mr. Leslie expressed his excitement following his appointment, citing Flora’s prospects that current clinical trials at the University of Manchester and in the United States can develop new, safe, plant-based medications to treat various conditions, including brain health pain and fibromyalgia. He acknowledged that the type of international growth Flora Growth is aiming for could prove difficult, but he has the experience given where he has worked before. “I hope to leverage that knowledge to assist the Flora team in making sound strategic decisions that will fuel Flora’s growth on an international scale,” he noted. “I truly believe in the potential of the cannabis industry to improve health, welfare and longevity of people around the globe. I feel that I have found the right fit in supporting this organization,” he added. Mr. Leslie also serves as an Executive in Residence at Beloit College and sits at the Board of Advisors of Endocanna Health and New Frontier Data. Additionally, investment company 360 Financial, Inc. recently announced owning 92 stocks with a total value of $219 million as of the last quarter of the 2021 financial year. Among the new purchases were 13,162 shares of Flora Growth, at a purchase price between $1.7 and $5.68 and an estimated average price of $3.44. The impact to the portfolio following this purchase was 0.01% (https://ibn.fm/xzMzH). For more information, visit the company’s website at www.FloraGrowth.com. NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

• Mydecine plans to launch a program to provide products and services to healthcare professionals, clinics, and hospitals in Canada looking to treat patients through psychedelic-assisted psychotherapy
• The products and services, which will be available for purchase as a package, include cGMP psilocybin and MDMA, therapy manuals, investigative brochures, protocol training, advisory services, and post-therapy support
• The planned launch follows an amendment to federal regulations allowing physicians to request and prescribe restricted drugs for treatment-resistant patients

Canada began the year on a high note by updating the Special Access Program (“SAP”), a move that demonstrates the government’s serious consideration of the potential of restricted substances to treat a range of conditions. The update removes a previous prohibition enacted in 2013 that outlawed the access of restricted drugs through the SAP. Starting this month, healthcare professionals can request patient access to restricted drugs, listed in Schedules I – V of the Controlled Drugs and Substances Act (“CDSA”), for treatment of life-threatening or serious conditions when other therapies have proven unsuccessful, are unavailable in Canada, or unsuitable. MDMA (more commonly known as ecstasy) and psilocybin are among the drugs patients can access through the updated SAP (https://ibn.fm/aFu31). As a direct response to the change, Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF), a biotechnology and digital technology company looking to transform the treatment of mental health and addiction disorders, on January 13 announced plans to launch The Special Access Support and Supply Program (“SASSP”). The program is intended to fill a critical void created by the update by providing products and services to thousands of physicians, clinics, and hospitals looking to treat patients through psychedelic-assisted psychotherapy (https://ibn.fm/O7CFD). In addition, the SASSP will offer A-Z support to medical practices across Canada, re-enforcing the safety and effective integration of psychedelic-based treatments. As part of the program, healthcare professionals can purchase a package that includes cGMP psilocybin and MDMA, therapy manuals, investigative brochures, protocol training, advisory services, and post-therapy support for patients through Mindleap Health, Mydecine’s wholly-owned subsidiary. Mydecine is currently producing cGMP certified pharmaceutical grade psilocybin and MDMA with coverage under a Health Canada Schedule 1 Drugs and Substances Dealer’s License in Alberta. Through the SASSP, the company believes it can help treat a significant patient population who need alternative treatment options for mental illnesses, particularly in cases where they have not responded to available evidence-based treatments. Notably, treatment resistance affects 20-60% of patients with mental illnesses/disorders (https://ibn.fm/QCeFp). With the Mental Health Commission of Canada noting that one in five people live with mental illnesses every year (about 7.6 million people today, based on the country’s population), treatment resistance indeed afflicts a significant population (https://ibn.fm/9ZNUN). “By launching this program, we are providing the resources the thousands of non-psychedelic clinics and hospitals will need in order to safely and effectively integrate these therapies into existing medical practices,” stated Mydecine CEO Josh Bartch. A 2016 study published in the Journal of Psychopharmacology and considered one of the first in the current psychedelic renaissance era established that a single dose of psilocybin lowered the rate of depression by 78% and anxiety by 83% six months after subjects had received treatment (https://ibn.fm/jJn12). Since then, numerous other studies have been conducted. A 2020 Johns Hopkins University study, for instance, showed that psilocybin with supportive psychotherapy relieves major depression, with half of study participants achieving remission through the four-week follow-up (https://ibn.fm/TnktS). Psilocybin has also been evaluated as a potential treatment for Post-Traumatic Stress Disorder (“PTSD”). A 2020 study found that “participants seemed to improve over time with respect to their symptoms of both PTSD and complicated grief” (https://ibn.fm/THVQv). Mydecine is also planning a Phase 2A clinical trial focusing on PTSD in front-line and emergency medical service (“EMS”) workers and veterans. This study will use the company’s lead drug candidate, MYCO-001, which is made up of 99% pure psilocybin. Relatedly, a 2021 study demonstrated that “MDMA-assisted therapy is highly efficacious in individuals with severe PTSD, and treatment is safe and well-tolerated, even in those with comorbidities,” concluding that MDMA-assisted therapy “represents a potential breakthrough treatment.” For more information, visit the company’s website at www.Mydecine.com. NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at https://ibn.fm/MYCOF

• In 2021, Delic’s investments and acquisitions allowed for an annualized revenue run-rate of over $9MM
• Going into the new year, the company looks forward to opening additional ketamine infusion treatment clinics, growing them by 15 within the next 18 months
• Delic’s growth has been attributed to the strong demand for alternatives to current treatments for mental health conditions
• Its management is confident that the foundations laid down so far position Delic for growth and profitability in 2022 and beyond

2021 was an excellent year for Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), as indicated in the company’s recent update (https://ibn.fm/HokJs), marked by key acquisitions and furthering its goal of providing the highest standard of care to patients. According to the management team, these achievements position the company well for growth and profitability in 2022 and beyond. In November 2021, Delic closed the acquisition of Ketamine Wellness Centers (“KWC”), an enterprise that operated 10 ketamine infusion treatment clinics across the United States (https://ibn.fm/K3Vug). The purchase brings the total number of operational Delic clinics to 12, making it the largest chain of wellness centers providing ketamine treatments in the United States. Delic is also confident that within the next 18 months, there will be 15 more clinics in operation, ultimately sealing its position as the undisputed leader in the segment. “At Delic, we have built the most profitable model for scaling the best-in-class care directly to patients through the largest network of mental health clinics in the U.S.,” noted Matt Stang, the Co-founder and Chief Executive Officer (“CEO”) of Delic. All acquisitions for the 2021 financial year were geared towards accelerating Delic’s growth trajectory and establishing its self-sustaining ecosystem of businesses that currently comprises Ketamine Infusion Centers (“KIC”), Delic Labs, KWC and a number of media properties. In total, these investments allowed for the company to realize an annualized revenue run-rate of over $9MM, a figure which the company is confident will be surpassed in 2022. Matt Stang, the Co-founder and Chief Executive Officer of Delic, has been keen to note that the company’s success has been primarily driven by the growing demand for alternatives to mainstream treatments for mental health conditions influenced by the ongoing pandemic. “We are seeing a strong demand for alternatives to current treatments with lasting outcomes and less side effects,” Mr. Stang noted. Delic’s media properties, including Meet Delic, arguably the world’s largest annual psychedelic wellness event, also demonstrate the power of the Delic ecosystem of businesses. In November 2021, it attracted over 2,500 attendees and over 2,000 inbound calls to clinics in a span of two days. Through achievements such as these, coupled with the company’s aggressive expansion and rollout, Delic is differentiating itself, with management confident in growth and profitability in 2022 and beyond. For more information, visit the company’s website at www.DelicCorp.com. NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF